Business and Finance

An analysis of the two main new models for pharmacy—unique direct—to-consumer for brands and cash pay for generics—and what members of industry think about them.

A dive into this market reveals that the latest numbers yield promising results—a global value of a worldwide $1.6 trillion—but it will continue to be attributed to past, present, and future healthcare spending.

Leading experts in the sector explore the value of third-party logistics providers when it comes to fortifying pharmaceutical supply chains.

Health Affairs study investigates the consequences of patient medication abandonment surrounding oral HIV pre-exposure prophylaxis.

In order to provide both profitability and medication access, a balancing act is required.

Duplicate rebates have resulted in revenue leakage for manufacturers.

Per the deal, the company establishes Regeneron Cell Medicines, while also providing it with access to the collection’s full development and commercialization rights.

Biogen and partner Eisai will shift focus to advancing Leqembi, the first anti-amyloid beta treatment for Alzheimer disease to be granted traditional approval by the FDA.

New England Journal of Medicine study provides a breakdown of how hospitals—especially those that qualify for discounts under the federal 340B Drug Pricing Program—are able to make a profit off insurer pharmaceutical expenditures.

The latest financial commitment adds 24,000 liters of biologics drug substance-capacity to the company’s network.

The definitive merger agreement was reached in October 2023, with Bristol Myers Squibb acquiring Mirati for $58 per share in cash, for a total equity value of $4.8 billion.

Acquisition is expected to strengthen company’s CDMO business, while establishing a footprint in the generics space.

Acquisition is expected to offer life sciences clients a boost in expertise and insight.

While often portrayed in a negative light, it is important to find a balanced perspective on its role in the pharma sector.

How pharma companies can be successful in financial forecasting, including why these forecasts should be powered by a patient-based approach.

In the face of chronic disease, DTx have the opportunity to provide a lifeline to patients.

MoU aims to align the pharmaceutical and cold chain sectors by boosting operations.

Pfizer said that the addition of Seagen to its current operations could add more than $10 billion in risk-adjusted revenues by 2030.

While new forms of pharmacy continue to surface beyond brick-and-mortar retail, a look at what is driving this shift in perspective—and "pharmacies of the future"—is warranted.

The designation—which ranks the fastest-growing companies in North America—is powered by AeroSafe’s 477% growth rate.

Purchase grows the company’s CRYOPDP domestic footprint while strengthening working relationship between both parties.

Parties will provide processing and packaging machinery services.

Stem Cell Reports takes a look at DTC online advertising claims that these are ‘immune boosters.’

Bayer said it will explore access options for patients with follicular lymphoma currently receiving Aliqopa who have experienced a favorable response to treatment.

Blue Fin Group exec speaks on his upcoming feature.

Financial commitment further strengthens IntegriChain’s platform as a source for pharma manufacturers' commercialization and market access goals.

Blue Fin Group executive highlights how leaders can plan for immediate profitable lifecycles and beyond.

SVP and Managing Director for Blue Fin Group offers a synopsis of the conference opener.

Session explains how to use this information to help bolster market intelligence, market access, and affordability strategies.

Conference presentation explores groundbreaking topics impacting the pharma industry.